Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Production Of coagulation factor VII in human cell lines Sk-Hep-1 and HBK-11

Full text
Author(s):
Correa de Freitas, Marcela Cristina ; Bomfim, Aline de Sousa ; Mizukami, Amanda ; Picanco-Castro, Virginia ; Swiech, Kamilla ; Covas, Dimas Tadeu
Total Authors: 6
Document type: Journal article
Source: Protein Expression and Purification; v. 137, p. 26-33, SEP 2017.
Web of Science Citations: 1
Abstract

Recombinant factor VII (rFVII) is the main therapeutic choice for hemophilia patients who have developed inhibitory antibodies against conventional treatments (FVIII and FIX). Because of the post translational modifications, rFVII needs to be produced in mammalian cell lines. In this study, for the first time, we have shown efficient rFVII production in HepG2, Sk-Hep-1, and HKB-11 cell lines. Experiments in static conditions for a period of 96 h showed that HepG2-FVII produced the highest amounts of rhFVII, with an average of 1843 ng/mL. Sk-hep-1-FVII cells reached a maximum protein production of 1432 ng/mL and HKB-11-FVII cells reached 1468 ng/mL. Sk-Hep-1-rFVII and HKB-11-rFVII were selected for the first step of scale-up. Over 10 days of spinner flask culture, HKB-11 and SK-Hep-1 cells showed a cumulative production of rFVII of 15214 and 202.6 mu g in 50 mL, respectively. Thus, these human cell lines can be used for an efficient production of recombinant FVII. With more investment in basic research, human cell lines can be optimized for the commercial production of different bio therapeutic proteins. (C) 2017 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 11/01736-5 - Cloning and expression of blood coagulation factor VII in human cell lines
Grantee:Marcela Cristina Corrêa de Freitas
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 16/02433-0 - Purification, formulation and preclinical testing of recombinant FVIII produced in human cells.
Grantee:Virginia Picanço e Castro
Support Opportunities: Regular Research Grants